公司資料
Kazia Therapeutics Limited 股價、新聞與催化劑
- 股票代碼:
- KZIA
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- Australia and listed in the U
股票表現
9.47 USD (-1.30%)
收盤價
最後更新: 2026年10月1日
135M USD
市值
股價為何變動
截至 2026年10月1日，KZIA 下跌 1.30%，收於 $9.47。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
業務概覽
Kazia Therapeutics is an oncology biotechnology company focused on targeted cancer therapies, including programs aimed at difficult solid tumors and brain tumors. Its story is built around trying to create meaningful value from a specialized oncology pipeline.
所在地與產業分類
Kazia is headquartered in Australia and listed in the U.S. market. It sits in small-cap oncology biotechnology.
商業模式特徵
The company depends on clinical data, translational confidence, and the ability to fund a narrow cancer pipeline. Investors usually watch proof-of-concept work and strategic changes.
生技產業定位
Kazia occupies a specialized oncology niche within biotech. It is highly catalyst-sensitive because the company is still proving whether the platform can matter clinically.
未來催化劑
- Kazia’s catalysts are paxalisib and the oncology / brain-cancer program, where the next update can materially change the market’s view. The stock remains very much a data story.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。